Angiotensin Converting Enzyme (ACE) Inhibitor Pipeline Insights, 2019 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Angiotensin
Converting Enzyme (ACE) Inhibitor -Pipeline Insight, 2019” drug
pipelines has been added to ResearchAndMarkets.com’s
offering.

Angiotensin Converting Enzyme (ACE) Inhibitor – Pipeline Insight, 2019
report offers comprehensive insights of the pipeline (under development)
therapeutics scenario and growth prospects across Angiotensin Converting
Enzyme (ACE) Inhibitor development. The report provides detailed
coverage of the pipeline landscape for this mechanism of action,
equipped with data from multiple sources with complete pipeline analysis
by developmental stage, associated indications, route of administration
and molecule type.

Descriptive coverage of pipeline development activities for Angiotensin
Converting Enzyme (ACE) Inhibitor – Pipeline therapeutics development
coverage provides descriptive product profiles including (but not
limited to) drug description, product development and R&D activities
encompassing clinical and pre-clinical studies, designations,
collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Angiotensin Converting Enzyme (ACE)
Inhibitor pipeline products by developmental stage, product type,
molecule type, and administration route.

Scope of the report

• Provides a snapshot of the therapeutics pipeline activity for
  Angiotensin Converting Enzyme (ACE) Inhibitor
• Features the Angiotensin Converting Enzyme (ACE) Inhibitor pipeline
  across the complete product development cycle including all clinical
  and non-clinical stages
• Offers detailed therapeutic product profiles of Angiotensin Converting
  Enzyme (ACE) Inhibitor with key coverage of developmental activities
  including licensing & collaboration deals, patent details,
  designations, technologies, indications and chemical information
• Therapeutic assessment of the active pipeline products by stage,
  product type, molecule type, and route of administration
• Coverage of dormant and discontinued pipeline projects across
  Angiotensin Converting Enzyme (ACE) Inhibitor

Key Topics Covered:

1. Report Introduction

2. Angiotensin Converting Enzyme (ACE) Inhibitor – Overview

3. Pipeline Therapeutics

• An Overview of Pipeline Products for Angiotensin Converting Enzyme
  (ACE) Inhibitor

4. Comparative Analysis

5. Angiotensin Converting Enzyme (ACE) Inhibitor Pipeline
Products in Clinical Stages

• Product Description
• Research and Development
• Product Development Activities

6. Angiotensin Converting Enzyme (ACE) Inhibitor Pipeline
Products in Non-clinical Stages

• Product Description
• Research and Development
• Product Development Activities

7. Therapeutic Assessment: Active Products

• Pipeline Assessment by Route of Administration
• Pipeline Assessment by Stage and Route of Administration
• Pipeline Assessment by Molecule Type
• Pipeline Assessment by Stage and Molecule Type

8. Inactive Pipeline Products

• Product Description
• Research and Development
• Product Development Activities
• Reason for dormancy/discontinuation

Companies Mentioned

• Gene PreDiT
• Marina Biotech
• Proveca
• Daewon Pharmaceutical
• Ethicare GmbH
• Ferrer
• Jeil Pharmaceutical

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/row3qq

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Cardiovascular
Drugs, Enzymes